#GLP-1 class
Coverage of the GLP-1 receptor agonist family and its successors.
Wegovy weight loss pill gets UK approval
The MHRA approved oral Wegovy (semaglutide 25 mg tablets) for weight management in adults on 11 June 2026, making it the first oral GLP-1 for obesity in the UK.
Optic neuropathy after semaglutide ramp-up
A 2026 case report describes atypical optic nerve damage behind the eye in a man on semaglutide 1 mg weekly, broadening the known spectrum of eye-related risks.
Biopsy-free MASH trials need longer runs
Ajmera and Loomba argue that NIT-based MASH trials must extend beyond 52 weeks and use composite non-invasive endpoints to capture fibrosis change.
Dulaglutide in 2026: still relevant?
A narrative review argues dulaglutide still earns its place in cardiometabolic care despite tirzepatide and semaglutide gaining ground.
GLP-1 add-on doubled time in range: Ramadan
A 2026 CGM study found that adding semaglutide or tirzepatide to insulin doubled time in range during Ramadan fasting without raising hypoglycaemia risk.
GLP-1 drugs cut CV risk in type 2 diabetes
A 2026 network meta-analysis finds GLP-1 therapies reduce mortality and MACE in type 2 diabetes. Semaglutide and albiglutide rank highest.
GLP-1 drugs tied to lower heart risk in RA
A TriNetX cohort study found GLP-1 therapy halved heart failure and respiratory failure risk in non-diabetic adults with RA and obesity.
Do GLP-1 drugs reduce fat graft survival?
A scoping review flags several mechanisms through which GLP-1 receptor agonists may reduce fat graft survival. No clinical data exist yet.
Oral semaglutide dropout rates in Japan
A Japanese database study found that high HbA1c and concurrent metformin use predicted early discontinuation of oral semaglutide at the 3 mg starting dose.
"Ozempic Face" Prevention: A New Risk Model
A 2026 paper proposes an anatomy-driven risk model and four-phase prevention algorithm for GLP-1-associated facial aging.
Semaglutide at 6 months: STEP trial data
Community posts report 80-90 lbs lost in six months on semaglutide. Here is what STEP trial data shows about timelines and plateaus.
Semaglutide and beta-cell function in T1D
A 2026 case study reports preserved beta-cell function and stable blood sugar in a newly diagnosed type 1 diabetes patient treated with semaglutide.